Spyre Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Spyre Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Spyre Therapeutics Inc Strategy Report
- Understand Spyre Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Spyre Therapeutics Inc (Spyre Therapeutics), formerly Aeglea BioTherapeutics Inc, is a clinical-stage biotechnology company. It develops and commercializes human enzymes for the treatment of enzyme therapeutics and rare metabolic diseases. The company’s program pipeline includes pegzilarginase, which is used for the treatment of arginase deficiency. Aeglea develops Pegtarviliase for treating classical homocystinuria, a rare disease caused due to hereditary genetic deficiency. The company also conducts preclinical programs for treating cystinuria and undisclosed rare diseases. It provides enzyme solutions to treat diseases with unmet medical needs. The company works in partnership with research institutions, healthcare providers and pharmaceutical companies. It provides its products across the US and the UK. Spyre Therapeutics is headquartered in Austin, Texas, the US.
Headquarters
United States of America
Address
221 Crescent Street, Suite 105, Waltham, Massachusetts, 02453
Website
spyre.com
Telephone
1 617 6515940
No of Employees
30
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SYRE (NASD)
Revenue (2022)
$886,000
-62%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-304.2%
(2022 vs 2021)
Market Cap*
$1.2B
Net Profit Margin (2022)
XYZ
-962.5%
(2022 vs 2021)
* As of and is in US$
Spyre Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Pegtarviliase: Classical Homocystinuria | Research Programs | Aeglea |
| Pegzilarginase: Arginase Deficiency |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Corporate Changes/Expansions | In November, the company changed its name to Spyre Therapeutics Inc. |
| 2023 | Acquisitions/Mergers/Takeovers | In June, the company announced the acquisition of Spyre Therapeutics, Inc. |
| 2020 | Contracts/Agreements | In October, the company announced that U.S. Food and Drug Administration has granted Orphan Drug Designation to ACN00177 for the treatment of Homocystinuria. |
Competitor Comparison
| Key Parameters | Spyre Therapeutics Inc | Bausch Health Companies Inc | Alnylam Pharmaceuticals Inc | Novavax Inc | Agilis Biotherapeutics LLC |
|---|---|---|---|---|---|
| Headquarters | United States of America | Canada | United States of America | United States of America | United States of America |
| City | Waltham | Laval | Cambridge | Gaithersburg | Cambridge |
| State/Province | Massachusetts | Quebec | Massachusetts | Maryland | Massachusetts |
| No. of Employees | 30 | 20,270 | 2,100 | 1,543 | 2,359 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Russell J Cox | Chairman | Executive Board | 2015 | 59 |
| Cameron Turtle | Chief Executive Officer; Director | Executive Board | 2023 | - |
| Scott Burrows | Chief Financial Officer | Senior Management | 2023 | - |
| Heidy Abreu King Jones | Chief Legal Officer; Corporate Secretary | Senior Management | 2023 | - |
| Linda Neuman | Chief Medical Officer | Senior Management | 2022 | 58 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer